1. R., Kasner S. E., Cucchiara B. L., Demchuck A., Tanne D., Ouyang B., Levine S. R. (2011). Dosing errors did not have a major impact on outcome in the NINDS t-PA stroke study.;Journal of Stroke and Cardiovascular Diseases
2. R., Tanne D., Demchuk A. M., Cucchiara B. L., Levine S. R., Kasner S. E. (2004). Dosing errors may Impact the risk of rtPA for stroke: The multicenter rtPA acute stroke survey.;Journal of Stroke and Cardiovascular Diseases
3. Tissue plasminogen activator for acute ischemic stroke.;New England Journal of Medicine,1995
4. L., Go S. A., Lloyd-Jones D. M., Adams R. J., Berry J. D., Brown T. M., Wylie-Rosett J.American Heart Association Statistics Committee and Stroke Statistics Subcommittee. (2011). Heart disease and stroke statistics2011 update: A report from the American Heart Association.;Circulation
5. J., Savor J. L, Jauch E. C., Adams H. P. JrAmerican Heart Association Stroke Council. (2009). Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart AssociationAmerican Stroke Association.;Stroke